Gatifloxacin
General
- Type: Fluoroquinolone
- Dosage Forms: Ophthalmic solution
- Common Trade Names: Zymar, Zymaxid
Adult Dosing
- 0.3% solution, 1 gtt in eye q2h up to 8x/day day 1 and 2, then QID x 5 days
- 0.5% solution, 1 gtt in eye q2h up to 8x/day first day, then bid-QID x 6 days
Pediatric Dosing
- > 1 y/o
- 0.3% solution, 1 gtt in eye q2h up to 8x/day day 1 and 2, then QID x 5 days
- 0.5% solution, 1 gtt in eye q2h up to 8x/day first day, then bid-QID x 6 days
Special Populations
- Pregnancy Rating: C
- Lactation: Safety Unknown
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Conjunctival hemorrhage
- Superinfection
Hypersensitivity reaction
Common
- Conjunctival irritation
- Ocular irritation
- Dysgeusia
- Ocular pain
- Chemosis
- Dry eyes
- Ocular discharge
- Blepharitis
- Headache
- Visual acuity changes
Pharmacology
- Half-life: N/A (7-14 hours for systemic preparations)
- Metabolism: Minimal
- Excretion: N/A (urine for systemic preparations)
- Mechanism of Action: Bactericidal, inhibits DNA gyrase and topoisomerase IV
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- Sanford Guide to Antimicrobial Therapy 2014
This article is issued from
Wikem.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.